

**Table E1. Average Tumor Weight**

Parameter	In Vivo Weight			Ex Vivo Weight
	Before Therapy	2 days after Therapy	2 weeks after Therapy	At Necropsy
Control	0.09 ± 0.08 (0.07–0.26)	0.22 ± 0.11 (0.07–0.39)	0.61 ± 0.40 (0.15–0.83)	0.56 ± 0.33 (0.21–0.76)
Pazopanib	0.02 ± 0.01 (0.004–0.05)	0.05 ± 0.04 (0.02–0.14)	0.14 ± 0.06 (0.08–0.25)	0.21 ± 0.06 (0.13–0.32)
<i>P</i> value*		<.026	.025*	<.036

Note.—Weight is in grams. Data are mean ± standard deviation unless otherwise indicated; data in parentheses are range. There were seven control animals; for pazopanib, before therapy there were seven animals and after therapy there were six animals.

\* *P* value is control versus pazopanib.

**Table E2. Average Tumor Volume**

Parameter	Day 0	Day 2	Day 4	Day 6	Day 8	Day 10	Day 12	Day 14	No. of Animals
Control	0.012 ± 0.004 (0.005–0.02)	0.06 ± 0.03 (0.32–0.11)	0.20 ± 0.13 (0.04–0.42)	0.26 ± 0.19 (0.07–0.53)	0.51 ± 0.39 (0.08–1.15)	0.68 ± 0.47 (0.20–1.35)	1.49 ± 0.63 (0.83–2.52)	1.68 ± 0.72 (0.91–2.83)	7
Pazopanib	0.011 ± 0.003 (0.005–0.01)	0.02 ± 0.01 (0.01–0.02)	0.08 ± 0.04 (0.03–0.12)	0.08 ± 0.05 (0.03–0.13)	0.08 ± 0.05 (0.31–0.17)	0.07 ± 0.01 (0.05–0.08)	0.26 ± 0.05 (0.21–0.32)	0.32 ± 0.04 (0.26–0.39)	7 or 6
<i>P</i> value, control vs pazopanib		<.00085	<.039	<.03	<.02	<.0083	<.00015	<.00014	
<i>P</i> value, comparison of days after treatment			2 d vs 4 d, <.0038	4 d vs 6 d, <.80	6 d vs 8 d, <.83	8 d vs 10 d, <.68	10 d vs 12 d, <.0000034	12 d vs 14 d, <.029	

Note.—Tumor volume is in cubic centimeters. Data are mean ± standard deviation unless otherwise indicated; data in parentheses are range. There were seven control animals; for pazopanib, before therapy there were seven animals and after therapy there were six animals.

**Table E3. Average Normalized Pyruvate/Pyruvate + Lactate**

Group	Normalized Lactate/(Pyruvate + Lactate)				No. of Animals	Difference Estimate, 2 days vs before Therapy
	Before Therapy	2 days after Therapy	2 weeks after Therapy			
Control	0.29 ± 0.10 (0.21–0.42)	0.35 ± 0.07 (0.24–0.45)	0.32 ± 0.05 (0.26–0.38)		7	0.06 ± 0.05
Pazopanib	0.31 ± 0.14 (0.19–0.57)	0.46 ± 0.07 (0.39–0.59)	0.37 ± 0.08 (0.30–0.46)		7 or 6	0.15 ± 0.06
Difference Estimate	0.02 ± 0.05	0.11 ± 0.05	0.04 ± 0.05			

Note.—Data are mean ± standard deviation unless otherwise indicated; data in parentheses are range. There were seven control animals; for pazopanib, before therapy there were seven animals and after therapy there were six animals. *P* value of change, control versus pazopanib, at 2 days was <.039. *P* value before treatment versus at 2 days after treatment was <.012.

**Table E4. Average Percent <sup>18</sup>F-FDG Dose Injected Per Gram**

Group	Before Therapy	2 days after Therapy	2 weeks after Therapy

Control	2.06 ± 1.84 (0.12–5.80)	1.81 ± 0.70 (0.88–2.60)	2.73 ± 2.20 (0.86–7.10)
Pazopanib	1.57 ± 0.36 (1.20–1.70)	2.31 ± 1.30 (0.35–3.90)	2.87 ± 1.56 (0.84–5.40)

Note.—Data are mean percentage of injected dose per gram ± standard deviation; data in parentheses are range. There were seven control animals; for pazopanib, before therapy there were seven animals and after therapy there were six animals.